Aberrant DNA methylation in ovarian cancer: Is there an epigenetic predisposition to drug response?

Annals of the New York Academy of Sciences

Volumn 983, Issue , 2003, Pages 243-250

  Wei, Susan H ^a   Brown, Robert ^b   Huang, Tim H M ^a,c  

^a University of Missouri   (United States)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF MISSOURI   (United States)

Author keywords

And mismatch repair; Chemotherapy; Cisplatin; DNA methylation; Drug resistance; High throughput; Microarray

Indexed keywords

CISPLATIN;

APOPTOSIS; CHROMATIN STRUCTURE; CONFERENCE PAPER; CPG ISLAND; DNA METHYLATION; DNA MICROARRAY; DNA REPAIR; DNA REPLICATION; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC PREDISPOSITION; HUMAN; HUMAN CELL; MISMATCH REPAIR; OVARY CANCER;

FALLOPIA;

EID: 0345701519     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2003.tb05979.x     Document Type: Conference Paper

References (27)

1. JONES, P.A. 1996. DNA methylation errors and cancer. Cancer Res. 56: 2463-2467.
2. BAYLIN, S.B., M. ESTELLER, M.R. ROUNDTREE, et al. 2001. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum. Mol. Genet. 10: 687-692.
3. SANTINI, V., M.K. HAGOP & J.P. ISSA. 2001. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann. Intern. Med. 134: 573-586.
4. COSTELLO, J.F. & C. PLANS. 2001. Methylation matters. J. Mol. Genet. 38: 285-303.
5. SOOD, A.K & R.E. BULLER. 1998. Drug resistance in ovarian cancer: from the laboratory to the clinic. Obstet. Gynecol. 92: 312-319.
6. COUKOS, G. & S.C. RUBIN. 1998. Chemotherapy resistance in ovarian cancer: new molecular perspectives. Obstet. Gynecol. 91: 783-792.
7. KARTALOU, M. & J.M. ESSIGMANN. 2001. Mechanisms of resistance to cisplatin. Mutat. Res. 478: 23-43.
8. BROWN, R, G.L. HIRST, W.M. GALLAGHER, et al. 1997. hMLH1 expression and cellular responses of ovarian tumor cells to treatment with cytotoxic anticancer agents. Oncogene 15: 45-52.
9. STRATHDEE, G., M.J. MACKEAN, M. ILLAND & R. BROWN. 1999. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 18: 2335-2341.
10. DRUMMOND, J.T., A.D. ANTHONEY, R. BROWN & P. MODRICK. 1996. Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumour cell line. J. Biol. Chem. 271: 19645-19648.
11. VAISMAN, A, M. VARCHENKO, A. UMAR, et al. 1998. The role of hMHL1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res. 58: 3579-3585.
12. FINK, D., S. AEBI & S.B. HOWELL. 1998. The role of DNA mismatch repair in drug resistance. Clin. Cancer Res. 4: 1-6.
13. ANTHONEY, D.A., A.J. MCILWRATH, W.M. GALLAGHER, et al. 1996. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. Cancer Res. 56: 1374-1381.
14. HUANG, T.H.-M., M.R. PERRY & D.E. LAUX. 1999. Methylation profiling of CpG islands in human breast cancer cells. Hum. Mol. Genet. 8: 459-470.
15. AHLUWALIA, A., P. YAN, J.A. HURTEAU, et al. 2001. DNA methylation and ovarian cancer. I. Analysis of CpG island hypermethylation in human ovarian cancer using differential methylation hybridization. Gynecol. Oncol. 82: 261-268.
16. YAN, P.S., C.-M. CHEN, H. SHI, et al. 2001. Dissecting complex epigenetic alterations in breast cancer using CpG island microarrays. Cancer Res. 61: 8375-8380.
17. WEI, S.H., C.-M. CHEN, G. STRATHDEE, et al. 2002. Methylation microarray analysis of late-stage ovarian carcinomas distinguishing progression-free survival in patients and identifies candidate epigenetic markers. Clin. Cancer Res. 8: 2246-2252.
18. YAN, P.S., T. EFFERTH, H.-L. CHEN, et al. 2002. Use of CpG island microarrays to identify colorectal tumors with a high degree of concurrent methylation. Methods Enzymol. 27: 162-169.
19. BEHRENS, B.C., T.C. HAMILTON, H. MASADU, et al. 1987. Characterization of a cis-diamminedichloroplatinum (11)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res. 47: 414-418.
20. 3 and its analogs on growth control and tumorigenesis. Front. Biosci. 6: d820-848.
21. NYCE J. 1989. Drug-induced DNA hypermethylation and drug resistance in human tumors. Cancer Res. 49: 5829-5836.
22. NEIJT, J.P. 1997. Textbook of Medical Oncology. Cavalli F, Hansen H.H. & S.B. Kaye Eds.: 87-115. Martin Dunitz Ltd. London.
23. FREDERIQUE, M., L.-M. BILLARD, G. WITTMANN, et al. 2000. Regional methylation of the 5′ end CpG island of BRACI is associated with reduced gene expression in human somatic cells. FASEB J. 14: 1585-1594.
24. FORGACS, E., S. ZOCHBAUER-MULLER, E. OLAH & J.D. MINNA. 2001. Molecular genetic abnormalities in the pathogenesis of human lung cancer. Pathol. Oncol. Res. 7: 6-13.
25. ISSA, J.P.J., A. NITA, M. TOYOTA, et al. 2001. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res. 61: 3573-3577.
26. GREENLEE, R.T., M.B. HILL-HARMON, T. MURRAY & M. THUN. 2001. Cancer statistics 2001. CA Cancer J. Clin. 51: 15-36.
27. WIDSCHWENDTER, M. & P.A. JONES. 2002. The potential prognostic, predictive, and therapeutic values of DNA methylation in cancer. Clin. Cancer Res. 8: 17-21.